These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

109 related articles for article (PubMed ID: 21093703)

  • 1. [Proposals to improve adherence to immunomodulatory therapies in patients with multiple sclerosis].
    Arroyo E; González M; Grau C; Arnal C; Bujanda M; de Castro P; Grau L; Martínez M; Ramo C; Sánchez V; Sánchez-Soliño O
    Neurologia; 2010; 25(9):544-51. PubMed ID: 21093703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Predicting ongoing adherence to disease modifying therapies in multiple sclerosis: utility of the health beliefs model.
    Turner AP; Kivlahan DR; Sloan AP; Haselkorn JK
    Mult Scler; 2007 Nov; 13(9):1146-52. PubMed ID: 17967842
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adherence to the immunomodulatory drugs for multiple sclerosis: contrasting factors affect stopping drug and missing doses.
    Tremlett H; Van der Mei I; Pittas F; Blizzard L; Paley G; Dwyer T; Taylor B; Ponsonby AL
    Pharmacoepidemiol Drug Saf; 2008 Jun; 17(6):565-76. PubMed ID: 18395883
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adherence to therapy in multiple sclerosis and schizophrenia].
    Bussfeld P; Czekalla J
    Fortschr Neurol Psychiatr; 2010 Mar; 78(3):139-46. PubMed ID: 20213580
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Objective adherence monitoring in multiple sclerosis: initial validation and association with self-report.
    Bruce JM; Hancock LM; Lynch SG
    Mult Scler; 2010 Jan; 16(1):112-20. PubMed ID: 19995835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term follow-up of clinical trials of multiple sclerosis therapies.
    Freedman MS
    Neurology; 2011 Jan; 76(1 Suppl 1):S26-34. PubMed ID: 21205679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addressing the need for increased adherence to multiple sclerosis therapy: can delivery technology enhance patient motivation?
    Lugaresi A
    Expert Opin Drug Deliv; 2009 Sep; 6(9):995-1002. PubMed ID: 19637982
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapy of multiple sclerosis in children and adolescents.
    Tenembaum SN
    Clin Neurol Neurosurg; 2010 Sep; 112(7):633-40. PubMed ID: 20471159
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adherence to disease-modifying therapies and attitudes regarding disease in patients with multiple sclerosis.
    Ožura A; Kovač L; Sega S
    Clin Neurol Neurosurg; 2013 Dec; 115 Suppl 1():S6-11. PubMed ID: 24321157
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence to disease-modifying drugs in patients with multiple sclerosis: a consensus statement from the Middle East MS Advisory Group.
    Yamout BI; Dahdaleh M; Al Jumah MA; Al-Shammri S; Al Sharoqi I; Al-Tahan AR; Bohlega S; Deleu D; Inshasi J; Khalifa A; Szólics M
    Int J Neurosci; 2010 Apr; 120(4):273-9. PubMed ID: 20374075
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Global adherence project to disease-modifying therapies in patients with relapsing multiple sclerosis: 2-year interim results].
    Arroyo E; Grau C; Ramo C; Parra J; Sánchez-Soliño O;
    Neurologia; 2010 Sep; 25(7):435-42. PubMed ID: 20964990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment effects of immunomodulatory therapies at different stages of multiple sclerosis in short-term trials.
    Bates D
    Neurology; 2011 Jan; 76(1 Suppl 1):S14-25. PubMed ID: 21205678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Persistence and adherence to disease modifying drugs among patients with multiple sclerosis.
    Reynolds MW; Stephen R; Seaman C; Rajagopalan K
    Curr Med Res Opin; 2010 Mar; 26(3):663-74. PubMed ID: 20070144
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improving patient self-management of multiple sclerosis through a disease therapy management program.
    Stockl KM; Shin JS; Gong S; Harada AS; Solow BK; Lew HC
    Am J Manag Care; 2010 Feb; 16(2):139-44. PubMed ID: 20148619
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fostering adherence to injectable disease-modifying therapies in multiple sclerosis.
    Lugaresi A; Rottoli MR; Patti F
    Expert Rev Neurother; 2014 Sep; 14(9):1029-42. PubMed ID: 25109614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical effects and tolerability of high-dose, high-frequency recombinant interferon beta-1a in patients with multiple sclerosis: maximizing therapy through long-term adherence.
    Boyko AN
    Expert Opin Biol Ther; 2010 Apr; 10(4):653-66. PubMed ID: 20218924
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started?
    Lonergan R; Kinsella K; Duggan M; Jordan S; Hutchinson M; Tubridy N
    Mult Scler; 2009 Dec; 15(12):1528-31. PubMed ID: 19995848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunomodulating drugs in multiple sclerosis: compliance, satisfaction and adverse effects evaluation in a German multiple sclerosis population.
    Twork S; Nippert I; Scherer P; Haas J; Pöhlau D; Kugler J
    Curr Med Res Opin; 2007 Jun; 23(6):1209-15. PubMed ID: 17559722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive dysfunction in multiple sclerosis: the effect of pharmacological interventions.
    Lyros E; Messinis L; Papageorgiou SG; Papathanasopoulos P
    Int Rev Psychiatry; 2010; 22(1):35-42. PubMed ID: 20222786
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Utilization of the multiple sclerosis functional composite in follow-up: relationship to disease phenotype, disability and treatment strategies.
    Ozakbas S; Ormeci B; Idiman E
    J Neurol Sci; 2005 May; 232(1-2):65-9. PubMed ID: 15850584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.